Long R3 IGF-1 is mainly supported by laboratory and biochemical research rather than established human treatment trials. Human benefit, dose and long-term safety are not defined.
Still uncertain: Human benefit, dosing, how the body handles it, long-term safety or performance/recovery benefit.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Modified IGF-1 analogue protein/peptide
Entity type
Protein / growth-factor-related biologic
Research focus
Growth-factor and muscle/tissue biology research
Human evidence
No verified therapeutic human trial programme for Long R3 IGF-1 itself was identified. Published evidence is dominated by biochemical/preclinical work and product-identity analysis.
Regulatory status
Long R3 IGF-1 is not the same product as FDA-approved mecasermin (recombinant human IGF-1).
Main limitations
Human efficacy, dosing, pharmacokinetics, long-term safety or performance/recovery benefit.
Safety
Systemic IGF-1 receptor activation can affect glucose and tissue growth; long-term safety of LR3 in humans is unknown.
Evidence reviewed
2026-09-18
i
No verified therapeutic human trial programme for Long R3 IGF-1 itself was identified. Published evidence is dominated by biochemical/preclinical work and product-identity analysis.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Systemic IGF-1 receptor activation can affect glucose and tissue growth; long-term safety of LR3 in humans is unknown.
Systemic IGF-1 receptor activation can affect glucose and tissue growth. Black-market product analyses have found oxidized or low-quality forms.
Technical details
Mechanism / biologyIGF-1 receptor agonism with modifications designed to alter binding-protein interactions and prolong activity.
Route / formulation boundaryDo not transfer clinical evidence for native IGF-1 or mecasermin to Long R3 IGF-1.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceStudy-regimen evidence reviewed. No verified therapeutic human dosing regimen identified; anti-doping literature documents the analogue but states IGF-I analogues such as Long R3 IGF-I were never approved for human use.
Identifiers & alternate namesIGF-1 LR3 · LR3 · Long R3 · Long R3 IGF-I
Source depth & provenance
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
2outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
PubMed / peer-reviewed source ↗ — Supports contraindication, interaction, monitoring, pregnancy or formulation-safety context in the safety evidence layer.
PubMed / peer-reviewed source ↗ — Documents Long R3 IGF-I as a synthetic IGF-I analogue that has not been approved for human use and describes analytical detection work.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
